查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1557323

肺炎鏈球菌疫苗市場 - 2024 年至 2029 年預測

Pneumococcal Vaccines Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 110 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球肺炎鏈球菌疫苗市場預計將以 6.49% 的複合年成長率成長，從 2024 年的 94.45 億美元增至 2029 年的 129.32 億美元。

有助於預防由肺炎鏈球菌引起的肺炎球菌疾病的疫苗被歸類為肺炎球菌疫苗。雖然肺炎球菌疾病在幼兒中最常見，但成人和老年人更容易受到肺炎球菌污染，甚至可能致命。疫苗接種是預防疾病傳播的廣泛接受的形式之一，並且正在推動對肺炎疫苗的需求。

定期國家疫苗接種計劃的實施正在支持市場成長。其次，人們對肺炎的認知不斷提高，世界衛生組織和聯合國兒童基金會發布的指令以及政府支持的增加正在支持當前情況下的市場擴張。

肺炎鏈球菌疫苗的全球市場促進因素

  • 兒童肺炎發病率的增加預計將推動對肺炎球菌疫苗的需求。

在兒童流行的感染疾病中，肺炎佔兒童死亡率的比例最高。每年有超過 80 萬名五歲以下兒童死於肺炎，即每天約有 2,200 名兒童。其中約 153,000 人是新生兒。根據聯合國兒童基金會的資料，每年每10萬人就有1,400人罹患肺炎，即71人中就有1人罹患肺炎。

南亞的發生率最高，為每 10 萬名兒童 2,500 例，西非和中非的發生率最高，為每 10 萬名兒童 1,620 例。這些數字對降低兒童死亡率、增加對肺炎球菌疫苗的需求和鼓勵市場擴張造成了令人震驚的局面。

  • 疾病意識提升宣傳活動和政府政策正在提供新的成長前景。

肺炎鏈球菌疫苗主要接種給 2 歲以上的兒童，以保護他們免受肺炎球菌引起的疾病。因此，世界衛生組織、聯合國兒童基金會和聯合國開發計畫署等多個國際組織正在與各國政府合作，降低肺炎感染的發生率，特別是特別容易感染此類疾病的兒童和老年人。

疫苗計劃的實施，例如衛生署根據全民免疫計劃在全國範圍內推廣肺炎球菌結合疫苗（PCV），有助於傳播對肺炎的認知，並為五歲以下兒童提供適當的疫苗。免疫系統。這些計劃和政策正在透過推出新產品和擴大現有產品系列來提振疫苗市場。

同樣，肺炎高發生率的各個低度開發國家也得到了國際組織的援助。例如，根據聯合國兒童基金會 2024 年 3 月的新聞稿，伊朗收到了約 564,000 劑肺炎球菌結合疫苗 (PCV)，以防止肺炎球菌相關感染疾病在兒童中傳播。在這樣的支持下，肺炎鏈球菌疫苗的市場正在不斷成長。

全球肺炎鏈球菌疫苗區隔市場分析

  • 預計結合疫苗將在特定時期內顯著成長。

依種類，國際上的肺炎鏈球菌疫苗可分為結合疫苗和多醣體疫苗。前者預計將出現顯著成長，因為它提供了針對肺炎和腦膜炎等疾病的免疫力，這些疾病主要發生在嬰幼兒和 65 歲以上的成年人中。對抗此類疾病的疫苗開發進展是該領域成長的主要動力。

例如，2023年4月，輝瑞宣布其PREVNAR 20(R)疫苗已獲得食品藥物管理局的核准。該疫苗可保護 6 週至 17 歲的嬰幼兒和兒童免受肺炎球菌引起的侵襲性肺炎鏈球菌感染。

預計北美將佔據重要的市場佔有率。

從地區來看，全球市場分為北美、南美、歐洲、中東/非洲、亞太地區五個主要區域。由於持續努力遏制兒童肺炎的傳播，預計北美將佔據重要的市場佔有率。因此，美國FDA 等主要監管機構已核准某些疫苗。

例如，2024年6月，默克公司宣布旨在為50歲及以上的成年人提供主動疫苗接種，覆蓋至少84%的由肺炎球菌血清型引起的侵襲性外科疾病。 FDA核准。同樣，各種生技疫苗製造商也處於肺炎鏈球菌疫苗開發舉措階段。例如，2024年1月，Vaxcyte Inc.宣布完成其VAX-31肺炎鏈球菌結合疫苗的臨床1/2期註冊，用於預防50歲及以上成年人的IPD（侵襲性肺炎鏈球菌感染）。

除了肺炎球菌疫苗的開發取得進展外，兒童肺炎盛行率的不斷上升也推動了整個北美市場的成長。例如，根據疾病預防控制中心提供的小兒肺炎最新資訊，截至2023年11月，0至1歲兒童肺炎急診就診率為1.7%，2歲兒童為2.4%至4歲兒童，2至4歲兒童為2.4%。

限制全球肺炎鏈球菌疫苗市場的因素：

  • 疫苗生產成本高昂預計將阻礙整體市場成長。

疫苗生產過程的高成本和長週期是市場成長的挑戰。此外，疫苗必須經歷的各個階段都需要適當的測試和監測才能達到預期的結果，這非常耗時。然而，政府對疫苗生產的補貼和國際組織宣布的資金正在幫助克服這一障礙。

全球肺炎鏈球菌疫苗主要市場開拓：

  • 2024年1月，輝瑞宣布CHMP（人用藥品委員會）對核准該公司的「20vPnC」採取了積極意見。
  • 2023 年 10 月，Vaxcyte Inc. 與 Lonza 簽訂了商業生產協議，以加強 Vaxcyte 的 PCV 候選藥物「VAX-31」和「VAX-24」的生產和商業化，以改善成人和老年人群的疾病控制。的傳播.此次合作利用了 Lonza 的自訂製造套件和基礎設施。

全球肺炎鏈球菌疫苗市場細分分析如下：

按類型

  • 結合疫苗
  • 多醣體疫苗

按用途

  • 常規疫苗接種
  • 疾病/感染疾病接種

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 美國英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他
  • 中東/非洲
  • 沙烏地阿拉伯
  • 以色列
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 印尼
  • 台灣
  • 泰國
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球肺炎鏈球菌疫苗市場：按類型

  • 介紹
  • 結合疫苗
  • 多醣體疫苗

第6章全球肺炎鏈球菌疫苗市場：依應用分類

  • 介紹
  • 常規疫苗接種
  • 疾病/感染疾病接種

第7章 按地區分類的肺炎鏈球菌市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 印尼
    • 台灣
    • 泰國
    • 其他

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Pfizer
  • GSK
  • Merck
  • AstraZeneca
  • Serum Institute of India Pvt Ltd
簡介目錄
Product Code: KSI061612059

The global pneumococcal vaccine market is estimated to grow at a CAGR of 6.49% and reach US$12.932 billion in 2029 from US$9.445 billion in 2024.

Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines. Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death. Immunization is one of the widely accepted forms to prevent disease spread, driving the demand for pneumonia vaccines.

Major driving factors, such as the implementation of regular vaccination programs under the national policy, are aiding the market's growth. Secondly, rising awareness against pneumonia, directives launched by WHO and UNICEF, and increasing government support assist the market's expansion in the current scenario.

Global Pneumococcal Vaccine Market Drivers

  • The growing incidence of childhood pneumonia is expected to drive the demand for pneumococcal vaccines.

Among all the infectious diseases prevalent among children, pneumonia has the highest share of fatalities in children. More than 800 thousand children under the age of five lose their lives every year due to pneumonia, while the number is around 2.2 thousand per day. Around 153 thousand of those children are newborns. According to data from UNICEF, 1,400 cases per 100,000 children suffer from pneumonia every year, which makes it 1 out of 71 children.

The South Asian region has the highest incidence rate, with 2,500 cases per 100,000 children, while the West and Central African region has an incidence rate of 1,620 cases per 100,000 children. These numbers are creating an alarming situation to combat child mortality rates, which is expanding the demand for pneumococcal vaccines, thereby stimulating their market expansion.

  • Growing disease awareness campaigns and government policies have provided new growth prospects.

Pneumococcal vaccines are given primarily to children aged 2 years and above to protect them from illness caused by S. pneumoniae bacteria. Hence, various International organizations like WHO, UNICEF, and UNDP, in conjunction with the national government, are working to reduce pneumonia infection rates, especially among the children and older generation who are more susceptible to such diseases.

The implementation of vaccine programs such as the nationwide expansion of pneumococcal conjugate vaccine (PCV) launched by the Ministry of Health under the "Universal Immunization Program" aimed to spread awareness against pneumonia and boost the immune system of children aged under 5 years through appropriate vaccines. These plans and policies boost the vaccine market by introducing novel products and expanding the existing product portfolios.

Likewise, various underdeveloped countries with higher prevalence rates of pneumonia are receiving aid from international organizations. For instance, as per the March 2024 UNICEF press release, Iran received nearly 564,000 doses of pneumococcal conjugate vaccine (PCV) to prevent pneumococcal-related infection from spreading among children; the shipment arrived in Tehran on March 17. Such assistance has led to an upward market trajectory for pneumococcal vaccines.

Global Pneumococcal Vaccine Market Segment Analysis

  • The conjugate vaccine is expected to show significant growth during the given time frame.

By type, the global pneumococcal vaccine is analyzed into the conjugate vaccine and polysaccharide vaccine. The former is anticipated to show remarkable growth as it provides immunity against diseases such as pneumonia and meningitis, which are mostly found in infants and adults aged 65 years and above. The ongoing vaccination development to battle such illnesses has provided a major boost to the segment's growth.

For instance, in April 2023, Pfizer announced that the company received the Food and Drug Administration's approval for its "PREVNAR 20(R)" vaccine. This vaccine would protect infants and children aged six weeks to 17 years against invasive pneumococcal disease caused by 20 S. pneumoniae.

North America is anticipated to account for a considerable market share.

Based on geography, the global market is analyzed into five major regions, namely North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America is estimated to constitute a remarkable market share, fuelled by the ongoing efforts to reduce pneumonia spread among children. This has led major governing authorities, such as the U.S. FDA, to grant approval to certain vaccines.

For instance, in June 2024, Merck received the U.S FDA's approval for its "CAPVAXIVE(TM)" vaccine, which is designed to provide active immunization to adults aged 50 years and above by covering at least 84% of invasive surgical diseases caused by S. pneumoniae serotypes. Likewise, various biotech vaccine manufacturers are in initiative phases for pneumococcal vaccine development. For instance, in January 2024, Vaxcyte Inc. announced the completion of enrolment for its clinical phase 1/2 to study the VAX-31 pneumococcal conjugate vaccine designed to prevent IPD (Invasive Pneumococcal Disease) in adults aged 50 years and above.

Besides the ongoing development of the pneumococcal vaccine, the growing prevalence of pneumonia in children is also driving the overall market growth in North America. For instance, according to the pediatric pneumonic update provided by the Center for Disease Control and Prevention, as of November 2023, the emergency visits diagnosed pneumonia stood at 1.7% for children aged 0 to 1 year, 2.4% for 2 to 4 years and 1.5% for 5 to 17 years.

Global Pneumococcal Vaccine Market Restraints:

  • The high cost of vaccine production is expected to hamper the overall market growth.

The high cost and long duration of the vaccine production process are challenging factors for market growth. Moreover, the various phases a vaccine has to go through require proper testing and monitoring to acquire the desired results, which is time-consuming. However, government subsidies on vaccine production and funds released by international organizations are helping to clear the hurdles in the path.

Global Pneumococcal Vaccine Key Market Development:

  • In January 2024, Pfizer announced that the CHMP (Committee for Medicinal Products for Humans) adopted a positive opinion regarding granting authorization to the company's "20vPnC." This will be used to prevent the spread of invasive diseases such as acute otitis and pneumonia in adults and children aged 6 weeks to 18 years.
  • In October 2023, Vaxcyte Inc. formed a commercial manufacturing agreement with Lonza to bolster the manufacturing and commercialization of Vaxcyte's PCV candidates "VAX-31" and "VAX-24" to prevent the disease spread in the adult and geriatric population. The collaboration will leverage Lonza's custom-manufacturing suite and infrastructure.

The Global Pneumococcal Vaccine market is segmented and analyzed as follows:

By Type

  • Conjugate Vaccines
  • Polysaccharide Vaccines

By Application

  • Routine Vaccination
  • Vaccination For Disease/Infection

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Conjugate Vaccines
  • 5.3. Polysaccharide Vaccines

6. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Routine Vaccination
  • 6.3. Vaccination for Disease/Infection

7. GLOBAL PNEUMOCOCCAL MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Indonesia
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Pfizer
  • 9.2. GSK
  • 9.3. Merck
  • 9.4. AstraZeneca
  • 9.5. Serum Institute of India Pvt Ltd